Vol. 5, Issue 2

Role of Hydroxyurea In Management of Sickle Cell Disease

Rakesh Amroliwala1, Vishruti Gandhi2, Niyati Parikh3, Arti Gupta4, Bhavi Shah5, Amit Jain6


1,2Associate Professor, 3,4,5,6Resident; Department of Paediatrics, SBKS Medical Institute & Research Centre, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat, India


Introduction: Sickle cell disease is an autosomal recessive chromosomal disorder. The prevalence of the sickle gene in India is found to vary from 2-34%. The clinical syndrome is a result of chronic anemia, and vaso-occlusion, which in turn can give rise to chronic damage. Hydroxyurea is a recommended treatment for sickle cell disease. Hydroxyurea is a myelosuppresive drug and is also indicated for other sickle cell-related complications, especially in patients who are unable to tolerate other treatments.
Materials and methods: All Hb electrophoresis proven sickle cell anemia children of age group between 6 months to 18 years of age coming to the OPD and ward of Pediatrics department of Dhiraj hospital were included in the study. They were subjected to routine investigations and management.
Result: The study was conducted on 70 patients with Hb electrophoresis proven sickle cell disease. After treatment with hydroxyurea for 9 months at mean dose of 25-30 mg/dl, patients improved symptomatically and clinically. Hb electrophoresis at 9 months showed a significant increase in mean HbF levels.
Key words: sickle cell disease, hydroxyurea, efficacy.